Paul Tudor Jones's ZVRA Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 443,109 shares of Zevra Therapeutics, Inc. (ZVRA) worth $4.13 M, representing 0.01% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in ZVRA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 244,201 shares. Largest reduction occurred in Q1 2026, reducing 248,988 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Zevra Therapeutics (ZVRA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Zevra Therapeutics (ZVRA) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -248,988 | Reduce 35.98% | 443,109 | $9.32 |
| Q4 2025 | +244,201 | Add 54.52% | 692,097 | $8.96 |
| Q3 2025 | +447,896 | New Buy | 447,896 | $9.51 |
Paul Tudor Jones's Zevra Therapeutics Investment FAQs
Paul Tudor Jones first purchased Zevra Therapeutics, Inc. (ZVRA) in Q3 2025, acquiring 447,896 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Zevra Therapeutics, Inc. (ZVRA) for 3 quarters since Q3 2025.
Paul Tudor Jones's largest addition to Zevra Therapeutics, Inc. (ZVRA) was in Q3 2025, adding 447,896 shares worth $4.26 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 443,109 shares of Zevra Therapeutics, Inc. (ZVRA), valued at approximately $4.13 M.
As of the Q1 2026 filing, Zevra Therapeutics, Inc. (ZVRA) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Zevra Therapeutics, Inc. (ZVRA) was 692,097 shares, as reported at the end of Q4 2025.